Nina Shah, MD

Articles

Dr. Shah on the Current State of Cellular Therapy in Multiple Myeloma

September 15th 2021

Nina Shah, MD, discusses the current state of cellular therapy in multiple myeloma.

Dr. Shah on Unmet Needs With CAR T-Cell Therapy in Multiple Myeloma

September 15th 2021

Nina Shah, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Dr. Shah on the Clinical Implications of Ide-Cel in Relapsed/Refractory Myeloma

September 10th 2021

Nina Shah, MD, discusses the clinical implications of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Dr. Shah on the Efficacy and Safety of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 28th 2021

Nina Shah, MD, discusses the efficacy and safety data observed with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr. Shah on Future Directions With CAR T-Cell Therapy in Multiple Myeloma

April 23rd 2021

Nina Shah, MD, discusses potential future directions with CAR T-cell therapy in multiple myeloma.

Dr. Shah on the Clinical Significance of Ide-Cel in Myeloma

April 21st 2021

Nina Shah, MD, discusses the clinical significance of idecabtagene vicleucel for the treatment of patients with multiple myeloma.

Dr. Shah on Managing CAR T-Cell Therapy–Related Toxicities in Multiple Myeloma

April 7th 2021

Nina Shah, MD, discusses the management of CAR T-cell therapy–related toxicities in multiple myeloma.

Dr. Shah on the Potential Rationale for Selecting Ide-Cel Vs Cilta-Cel In Multiple Myeloma

March 26th 2021

Nina Shah, MD, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr. Shah on the Importance of Assessing Quality of Life in Multiple Myeloma

December 15th 2020

Nina Shah, MD, discusses the importance of assessing quality of life in multiple myeloma.

Dr. Shah on Early Benefit of Orvacabtagene Autoleucel in Relapsed/Refractory Myeloma

September 3rd 2020

Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr. Shah on BCMA-Directed CAR T-Cell Therapy Research in R/R Multiple Myeloma

August 14th 2020

Nina Shah, MD, discusses ​ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Shah on Updated Efficacy of JNJ-4528 in Relapsed/Refractory Myeloma

August 12th 2020

Nina Shah, MD, discusses the updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Dr. Shah on the Future of CAR T-Cell Therapy in Multiple Myeloma

August 12th 2020

Nina Shah, MD, discusses the future of CAR T-cell therapy in multiple myeloma. 

Dr. Shah on the Role of Venetoclax in Multiple Myeloma

April 23rd 2020

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of venetoclax (Venclexta) in multiple myeloma.

Dr. Shah on Potential for Daratumumab Maintenance in Multiple Myeloma

February 7th 2020

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the potential for daratumumab (Darzalex) maintenance therapy in multiple myeloma.

Dr. Shah on Daratumumab-Based Regimens in Frontline Multiple Myeloma

January 28th 2020

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses daratumumab (Darzalex)-based regimens in the frontline treatment of patients with multiple myeloma.

Dr. Shah on the Utility of MRD in Frontline Multiple Myeloma

January 13th 2020

Nina Shah, MD, discusses the utility of minimal residual disease in frontline multiple myeloma.

Dr. Shah on the Curative Potential of CAR T-Cell Therapy in Myeloma

February 8th 2019

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the curative potential of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Shah Discusses Challenges With CAR T-Cell Therapy in Myeloma

January 15th 2019

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Shah Discusses Potential of bb21217 in Multiple Myeloma

January 9th 2019

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the potential of bb21217 in the treatment of patients with multiple myeloma.